EP0366707A1
(en)
|
1987-05-06 |
1990-05-09 |
OOSTERWIJK, Egbert |
Monoclonal antibodies to renal cell carcinoma
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
JPH03503840A
(ja)
|
1988-01-15 |
1991-08-29 |
セントコアー,インコーポレーテッド |
異種連結抗体およびその治療的使用
|
AU8727291A
(en)
|
1990-10-29 |
1992-06-11 |
Cetus Oncology Corporation |
Bispecific antibodies, method of production, and uses thereof
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
DE69332948T2
(de)
|
1992-03-05 |
2003-11-27 |
Univ Texas |
Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
US6036955A
(en)
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
WO1996034892A1
(en)
|
1995-05-03 |
1996-11-07 |
Bioenhancements Ltd. |
Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
|
DE19531346A1
(de)
|
1995-08-25 |
1997-02-27 |
Gsf Forschungszentrum Umwelt |
Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
TR200003087T2
(tr)
|
1998-04-21 |
2001-02-21 |
Micromet Ag |
Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
US6534633B1
(en)
|
1998-10-21 |
2003-03-18 |
Altor Bioscience Corporation |
Polyspecific binding molecules and uses thereof
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2001071005A2
(en)
|
2000-03-24 |
2001-09-27 |
Micromet Ag |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
US20040115198A1
(en)
|
2001-02-28 |
2004-06-17 |
Fred Hutchinson Cancer Research Center |
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
DE10156482A1
(de)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispezifisches Antikörper-Molekül
|
RU2339647C2
(ru)
|
2002-08-19 |
2008-11-27 |
Астразенека Аб |
Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
DE10261223A1
(de)
|
2002-12-20 |
2004-07-08 |
MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH |
Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
|
RU2005127664A
(ru)
|
2003-02-06 |
2006-09-10 |
Микромет Аг (De) |
Тримерная полипептидная конструкция, индуцирующая пролонгированный т-клеточный ответ
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
US8784821B1
(en)
|
2003-05-31 |
2014-07-22 |
Amgen Research (Munich) Gmbh |
Human-anti-human cd3 binding molecules
|
RU2005141512A
(ru)
|
2003-05-31 |
2007-07-20 |
Микромет Аг (De) |
Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
BRPI0415457A
(pt)
|
2003-10-16 |
2006-12-05 |
Micromet Ag |
constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
CA2555503C
(en)
|
2004-02-16 |
2018-03-27 |
Micromet Ag |
Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
|
MX2007000387A
(es)
|
2004-07-16 |
2007-03-28 |
Micromet Ag |
Polipeptidos de expresion mejorada.
|
KR20160096228A
(ko)
|
2004-07-22 |
2016-08-12 |
제넨테크, 인크. |
Her2 항체 조성물
|
MX2007003910A
(es)
|
2004-10-01 |
2007-06-07 |
Avidex Ltd |
Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
WO2007002905A1
(en)
*
|
2005-06-29 |
2007-01-04 |
University Of Miami |
Antibody-immune cell ligand fusion protein for cancer therapy
|
WO2007022520A2
(en)
|
2005-08-19 |
2007-02-22 |
Cerus Corporation |
Antibody-mediated enhancement of immune response
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
JP5686953B2
(ja)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用
|
CN101300272B
(zh)
|
2005-10-14 |
2013-09-18 |
依奈特制药公司 |
用于治疗增生性病症的组合物和方法
|
JP2009513608A
(ja)
|
2005-10-28 |
2009-04-02 |
ノボ・ノルデイスク・エー/エス |
エフェクターリンパ球と標的細胞とを結合する融合タンパク質
|
JP2009514528A
(ja)
|
2005-11-03 |
2009-04-09 |
フレッド ハッチンソン キャンサー リサーチ センター |
Nkg2d陽性cd4+細胞による免疫応答の負の免疫調節法
|
WO2007097812A2
(en)
|
2005-11-03 |
2007-08-30 |
Genentech, Inc. |
Therapeutic anti-her2 antibody fusion polypeptides
|
DK1976886T3
(en)
|
2005-12-16 |
2015-03-02 |
Amgen Res Munich Gmbh |
Means and methods for the treatment of tumor diseases
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
CA2654317A1
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
EA017203B1
(ru)
|
2006-09-07 |
2012-10-30 |
Круселл Холланд Б.В. |
Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
|
EP1900752A1
(en)
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
CN101802197A
(zh)
|
2007-05-14 |
2010-08-11 |
比奥根艾迪克Ma公司 |
单链FC(ScFc)区、包含其的结合多肽及与其相关的方法
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
ES2320076B2
(es)
|
2007-07-11 |
2010-01-26 |
La Morella Nuts, S.A. |
Procedimiento en continuo de fabricacion de productos alimenticios.
|
WO2009013543A2
(en)
|
2007-07-25 |
2009-01-29 |
Astrazeneca Ab |
Targeted binging agents directed to kdr and uses thereof - 035
|
WO2009023270A2
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
CA2697193C
(en)
|
2007-09-14 |
2017-06-06 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP2222706B2
(en)
*
|
2007-12-14 |
2016-08-10 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
PL2235064T3
(pl)
|
2008-01-07 |
2016-06-30 |
Amgen Inc |
Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
|
CN101977937A
(zh)
|
2008-01-22 |
2011-02-16 |
拜奥根Idec马萨诸塞公司 |
Ron抗体及其用途
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
US9273136B2
(en)
|
2008-08-04 |
2016-03-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human anti-human NKG2D monoclonal antibodies
|
JP2012503490A
(ja)
|
2008-09-26 |
2012-02-09 |
ワイス・エルエルシー |
単鎖抗体ライブラリー設計
|
EP2356146A1
(en)
|
2008-11-07 |
2011-08-17 |
Fabrus Llc |
Anti-dll4 antibodies and uses thereof
|
CA2747011C
(en)
|
2008-12-18 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Nkg2d-fc for immunotherapy
|
BRPI0918122A8
(pt)
|
2008-12-19 |
2017-01-24 |
Macrogenics Inc |
molécula de diabody, diabody, e mólecula dart
|
SG175081A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Bispecific anti-erbb-3/anti-c-met antibodies
|
EP2429584A4
(en)
|
2009-05-13 |
2013-02-20 |
Genzyme Corp |
TREATMENT PROCEDURE AND COMPOSITIONS
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
US20130209514A1
(en)
|
2009-06-09 |
2013-08-15 |
Eli Gilboa |
Aptamer-targeted costimulatory ligand aptamer
|
ES2536996T3
(es)
|
2009-07-06 |
2015-06-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos biespecíficos de unión a digoxigenina
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011030851A1
(ja)
|
2009-09-11 |
2011-03-17 |
タカラバイオ株式会社 |
ナチュラルキラー細胞の製造方法
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
HUE025759T2
(en)
|
2009-10-27 |
2016-04-28 |
Amgen Res (Munich) Gmbh |
Dosage system for administering CD19xCD3 bispecific antibody
|
WO2011057124A1
(en)
|
2009-11-06 |
2011-05-12 |
Transtarget, Inc. |
Polyclonal bispecific antibody compositions and method of use
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
TW201132353A
(en)
|
2009-12-18 |
2011-10-01 |
Amgen Inc |
WISE binding agents and epitopes
|
US8658765B2
(en)
|
2009-12-31 |
2014-02-25 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
US20120294857A1
(en)
|
2010-01-11 |
2012-11-22 |
Trustees Of Dartmouth College |
Monomeric Bi-Specific Fusion Protein
|
ME03447B
(me)
|
2010-03-04 |
2020-01-20 |
Macrogenics Inc |
Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
CN103097417B
(zh)
|
2010-04-20 |
2019-04-09 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
CN105001330B
(zh)
|
2010-04-23 |
2020-05-01 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
KR101834026B1
(ko)
|
2010-06-19 |
2018-03-02 |
메모리얼 슬로안-케터링 캔서 센터 |
항-gd2 항체
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
DE102010039018B4
(de)
|
2010-08-06 |
2013-02-28 |
Technische Universität Dresden |
Anti-La Antikörper und ihre Anwendung zum Immunotargeting
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
EP2609111B1
(en)
|
2010-08-24 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising a disulfide stabilized-fv fragment
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
NZ607510A
(en)
|
2010-09-10 |
2014-10-31 |
Apexigen Inc |
Anti-il-1 beta antibodies and methods of use
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
US20120263722A1
(en)
|
2010-11-04 |
2012-10-18 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
US9518132B2
(en)
|
2010-11-09 |
2016-12-13 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
BR112013021526B1
(pt)
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
|
JP5972915B2
(ja)
|
2011-03-16 |
2016-08-17 |
アムジエン・インコーポレーテツド |
Fc変異体
|
CN107840894A
(zh)
|
2011-03-25 |
2018-03-27 |
格兰马克药品股份有限公司 |
异二聚体免疫球蛋白
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
US20140234342A1
(en)
|
2011-06-21 |
2014-08-21 |
Innate Pharma |
Nkp46-mediated nk cell tuning
|
DE102011118022B4
(de)
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
EP2728002B1
(en)
|
2011-06-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
BR112014001573B8
(pt)
|
2011-07-22 |
2022-11-08 |
Affimed Therapeutics Ag |
Molécula fv ao antígeno multivalente
|
US10040853B2
(en)
|
2011-09-09 |
2018-08-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving NKG2D inhibitors and cancer
|
KR102276528B1
(ko)
|
2011-09-30 |
2021-07-12 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존성 결합 분자 라이브러리
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
EA201400709A1
(ru)
|
2011-12-19 |
2016-08-31 |
Синиммун Гмбх |
Молекула биспецифического антитела
|
EP2812356B1
(en)
|
2012-02-08 |
2019-03-27 |
IGM Biosciences, Inc. |
Cdim binding proteins and uses thereof
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
US9029510B2
(en)
|
2012-03-30 |
2015-05-12 |
Sorrento Therapeutics, Inc. |
Fully human antibodies that bind to VEGFR2 and methods of use thereof
|
KR20230091201A
(ko)
|
2012-04-20 |
2023-06-22 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
TWI617578B
(zh)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
標的組織專一的抗原結合分子
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
CA2877573A1
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
BR112015000798A2
(pt)
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
|
WO2014018572A2
(en)
|
2012-07-23 |
2014-01-30 |
Zymeworks Inc. |
Immunoglobulin constructs comprising selective pairing of the light and heavy chains
|
WO2014022540A1
(en)
|
2012-08-02 |
2014-02-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent antigen-binding proteins
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
TR201815768T4
(tr)
|
2012-09-27 |
2018-11-21 |
Merus Nv |
T hücre bağlayıcılar olarak bispesifik IgG antikorları.
|
CA2892059C
(en)
|
2012-11-21 |
2023-02-14 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
WO2014084607A1
(ko)
|
2012-11-27 |
2014-06-05 |
아주대학교산학협력단 |
항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
|
EP2943506B1
(en)
|
2013-01-10 |
2024-03-13 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
ES2829499T3
(es)
|
2013-02-05 |
2021-06-01 |
Engmab Sarl |
Método para la selección de anticuerpos contra BCMA
|
EP2954056A4
(en)
|
2013-02-08 |
2016-09-21 |
Stemcentrx Inc |
NEW MULTISPECIFIC CONSTRUCTIONS
|
JP6133444B2
(ja)
|
2013-02-26 |
2017-05-24 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
SG11201507424WA
(en)
|
2013-03-14 |
2015-10-29 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
WO2014150973A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
CN105377889B
(zh)
|
2013-03-15 |
2020-07-17 |
Xencor股份有限公司 |
异二聚体蛋白
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
US20140323315A1
(en)
|
2013-04-29 |
2014-10-30 |
Adimab, Llc |
Polyspecificity reagents, methods for their preparation and use
|
CN105408356A
(zh)
|
2013-05-10 |
2016-03-16 |
努玛有限公司 |
双特异性构建体及其用于治疗多种疾病的用途
|
US10174117B2
(en)
|
2013-06-11 |
2019-01-08 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
|
CN105612183A
(zh)
*
|
2013-07-15 |
2016-05-25 |
诺和诺德股份有限公司 |
结合尿激酶纤溶酶原激活物的抗体
|
CA2916681A1
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
EP3406633B1
(en)
|
2013-07-25 |
2022-03-02 |
Cytomx Therapeutics Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
CN105636982B
(zh)
|
2013-09-16 |
2020-06-23 |
健康与环境慕尼黑德国研究中心赫姆霍茨中心(有限责任公司) |
用于治疗hbv感染和相关病症的结合免疫效应细胞表面抗原和hbv抗原的双或多特异性多肽
|
GB2518221A
(en)
|
2013-09-16 |
2015-03-18 |
Sergej Michailovic Kiprijanov |
Tetravalent antigen-binding protein molecule
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
CN106414500B
(zh)
|
2013-11-07 |
2020-04-10 |
纪念斯隆-凯特琳癌症中心 |
抗-wt1/hla双特异性抗体
|
DE102013019352A1
(de)
|
2013-11-13 |
2015-09-17 |
Elke Pogge Von Strandmann |
Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
|
KR102357906B1
(ko)
|
2013-11-27 |
2022-02-03 |
자임워크스 인코포레이티드 |
Her2를 표적화하는 이중특이성 항원-결합 작제물
|
AR098743A1
(es)
|
2013-12-13 |
2016-06-08 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
WO2015095412A1
(en)
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
EP3327038B1
(en)
|
2013-12-20 |
2020-09-23 |
F. Hoffmann-La Roche AG |
Bispecific her2 antibodies and methods of use
|
CA3204788A1
(en)
|
2013-12-20 |
2015-06-25 |
Genentech, Inc. |
Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
|
WO2015095972A1
(en)
|
2013-12-23 |
2015-07-02 |
The Centre For Drug Research And Development |
Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
|
NZ720353A
(en)
|
2013-12-30 |
2019-12-20 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
MX2016009050A
(es)
|
2014-01-15 |
2016-12-09 |
Zymeworks Inc |
Construcciones biespecificas de union a los antigenos cd3 y cd19.
|
KR102235202B1
(ko)
|
2014-03-05 |
2021-04-05 |
유씨엘 비즈니스 리미티드 |
T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car)
|
CA2943834A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
WO2015153765A1
(en)
|
2014-04-01 |
2015-10-08 |
Adimab, Llc |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
SI3126383T1
(sl)
|
2014-04-03 |
2019-05-31 |
Igm Biosciences, Inc. |
Modificirana veriga J
|
JP2017512765A
(ja)
|
2014-04-11 |
2017-05-25 |
メディミューン,エルエルシー |
二重特異性her2抗体
|
EP2930188A1
(en)
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
EP2942629A1
(en)
|
2014-05-08 |
2015-11-11 |
Universität Würzburg |
Predictive markers for successful cancer immunotherapy
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
NZ726520A
(en)
|
2014-05-29 |
2018-12-21 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
EP3161002A1
(en)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
MULTISPECIFIC NKp46 BINDING PROTEINS
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
WO2015197582A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Monomeric multispecific antigen binding proteins
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
US10556964B2
(en)
|
2014-07-21 |
2020-02-11 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
US9777073B2
(en)
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
JP6390239B2
(ja)
|
2014-07-25 |
2018-09-19 |
富士ゼロックス株式会社 |
情報処理装置、及びプログラム
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
CN107106677A
(zh)
|
2014-08-28 |
2017-08-29 |
莱顿大学学术医院以Lumc的名义运作 |
Cd94/nkg2a和/或cd94/nkg2b抗体、疫苗组合
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
CA2966397A1
(en)
|
2014-11-03 |
2016-05-12 |
Merck Patent Gmbh |
Methods for generating bispecific shark variable antibody domains and use thereof
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
JP2017537617A
(ja)
|
2014-12-05 |
2017-12-21 |
アビッドバイオティクス コーポレイション |
抗体の挿入可能な可変フラグメントおよびnkg2dリガンドの改変α1−α2ドメイン
|
EP3233122A4
(en)
|
2014-12-17 |
2018-09-19 |
Intrexon Corporation |
Intercalated single-chain variable fragments
|
KR102495820B1
(ko)
|
2014-12-19 |
2023-02-06 |
치오메 바이오사이언스 가부시키가이샤 |
5t4 및 cd3에 대한 3개 결합 도메인을 포함하는 융합 단백질
|
CN114316061A
(zh)
|
2015-01-02 |
2022-04-12 |
武田药品工业株式会社 |
针对血浆激肽释放酶和因子xii的双特异性抗体
|
WO2016115274A1
(en)
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
WO2016122701A1
(en)
|
2015-01-26 |
2016-08-04 |
Macrogenics, Inc. |
Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
|
KR102606190B1
(ko)
|
2015-02-20 |
2023-11-23 |
오하이오 스테이트 이노베이션 파운데이션 |
Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016142768A1
(en)
|
2015-03-10 |
2016-09-15 |
Eureka Therapeutics, Inc. |
Ror2 antibody
|
CN107223135B
(zh)
|
2015-03-16 |
2021-11-02 |
亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) |
用于治疗hbv感染和相关病症的三特异性结合分子
|
JP6903587B2
(ja)
|
2015-04-03 |
2021-07-14 |
ユーリカ セラピューティックス, インコーポレイテッド |
Afpペプチド/mhc複合体を標的化する構築物およびその使用
|
CA2981711A1
(en)
|
2015-04-06 |
2016-10-13 |
Subdomain, Llc |
De novo binding domain containing polypeptides and uses thereof
|
SG10201912087SA
(en)
|
2015-04-07 |
2020-02-27 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
WO2016187220A2
(en)
|
2015-05-18 |
2016-11-24 |
Five Prime Therapeutics, Inc. |
Anti-ror1 antibodies
|
EP3095792A1
(en)
|
2015-05-19 |
2016-11-23 |
Klinikum rechts der Isar der Technischen Universität München |
T cell receptor with specificity for myeloperoxidase peptide and uses thereof
|
US20180147257A1
(en)
|
2015-05-22 |
2018-05-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Btn3a ectodomain proteins and methods of use
|
SG10201913500TA
(en)
|
2015-05-29 |
2020-03-30 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
US20180237534A1
(en)
|
2015-05-29 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
JP2018518491A
(ja)
|
2015-06-12 |
2018-07-12 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
JP2018522833A
(ja)
|
2015-06-12 |
2018-08-16 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療
|
CA2990511A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
EP3313881A1
(en)
|
2015-06-23 |
2018-05-02 |
Innate Pharma |
Multispecific nk engager proteins
|
KR20180027566A
(ko)
|
2015-07-06 |
2018-03-14 |
유씨비 바이오파마 에스피알엘 |
타우 결합 항체
|
US20180194861A1
(en)
|
2015-07-10 |
2018-07-12 |
Abbvie Inc. |
IgM- or IgE-Modified Binding Proteins and Uses Thereof
|
CA2991799A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
EP3322449A1
(en)
|
2015-07-16 |
2018-05-23 |
Cellerant Therapeutics, Inc. |
Cysteine-substituted immunoglobulins
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
AU2016322934A1
(en)
|
2015-09-14 |
2018-04-12 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
|
EP3356403A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific antibodies specific for a costimulatory tnf receptor
|
CN108431041B
(zh)
|
2015-10-29 |
2022-08-16 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
KR20180083874A
(ko)
|
2015-11-04 |
2018-07-23 |
사울 제이. 프라이스맨 |
Her2를 표적화하는 키메라 항원 수용체
|
US10815290B2
(en)
|
2015-11-10 |
2020-10-27 |
Fred Hutchinson Cancer Research Center |
NKG2D decoys
|
WO2017081190A1
(en)
|
2015-11-13 |
2017-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
AU2016383475B2
(en)
|
2015-12-28 |
2024-02-22 |
Innate Pharma |
Variable regions for NKp46 binding proteins
|
US20190031785A1
(en)
|
2016-01-13 |
2019-01-31 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
UY37127A
(es)
|
2016-02-17 |
2017-08-31 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
WO2017143406A1
(en)
|
2016-02-26 |
2017-08-31 |
Imunexus Pty Ltd |
Multi-specific molecules
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
BR112018070676A2
(pt)
|
2016-04-15 |
2019-02-05 |
Zymeworks Inc |
construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
|
JP7002467B2
(ja)
|
2016-04-15 |
2022-01-20 |
マクロジェニクス,インコーポレーテッド |
新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
|
GB201610044D0
(en)
|
2016-06-08 |
2016-07-20 |
Ucb Biopharma Sprl |
Antibodies
|
KR102523402B1
(ko)
|
2016-06-14 |
2023-04-19 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
CN105906722B
(zh)
|
2016-06-24 |
2020-02-07 |
安徽未名细胞治疗有限公司 |
一种Her2特异性嵌合抗原受体及其应用
|
CA3035254A1
(en)
|
2016-09-01 |
2018-03-08 |
Immunomab, Inc. |
Bispecific antibodies
|
WO2018071777A1
(en)
|
2016-10-14 |
2018-04-19 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
US20200095327A1
(en)
|
2017-02-08 |
2020-03-26 |
Dragonfly Therapeutics, Inc. |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
CA3053010A1
(en)
|
2017-02-08 |
2018-08-16 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
CN110461361A
(zh)
*
|
2017-02-10 |
2019-11-15 |
蜻蜓治疗公司 |
结合bcma、nkg2d和cd16的蛋白
|
KR20190120770A
(ko)
|
2017-02-10 |
2019-10-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Psma, nkg2d 및 cd16에 결합하는 단백질
|
WO2018152547A1
(en)
|
2017-02-20 |
2018-08-23 |
Adimab, Llc |
Proteins binding cd123, nkg2d and cd16
|
WO2018152516A1
(en)
|
2017-02-20 |
2018-08-23 |
Adimab, Llc |
Proteins binding cd33, nkg2d and cd16
|
MX2019009943A
(es)
|
2017-02-20 |
2019-12-19 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a gd2, nkg2d y cd16.
|
MX2019009848A
(es)
|
2017-02-20 |
2019-12-19 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a her2, nkg2d y cd16.
|
US20210130496A1
(en)
|
2017-02-27 |
2021-05-06 |
Dragonfly Therapeutics, Inc. |
Multispecific binding proteins targeting cea
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3630181A4
(en)
|
2017-05-23 |
2021-03-17 |
Dragonfly Therapeutics, Inc. |
NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
|
CN111278455A
(zh)
|
2017-05-23 |
2020-06-12 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
AU2018271872A1
(en)
|
2017-05-23 |
2019-12-12 |
Dragonfly Therapeutics, Inc. |
A protein binding NKG2D, CD16 and ROR1 or ROR2
|
CN111132698A
(zh)
|
2017-07-31 |
2020-05-08 |
蜻蜓治疗公司 |
结合nkg2d、cd16以及flt3的蛋白质
|
WO2019035939A1
(en)
|
2017-08-16 |
2019-02-21 |
Dragonfly Therapeutics, Inc. |
PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
|
AU2018322178A1
(en)
|
2017-08-23 |
2020-02-20 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
JP7431392B2
(ja)
|
2017-09-07 |
2024-02-15 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
NKG2D、CD16およびNectin4に結合するタンパク質
|
EP3681532A4
(en)
|
2017-09-14 |
2021-09-01 |
Dragonfly Therapeutics, Inc. |
NKG2D, CD1 6 AND TYPE LECTIN LIKE MOLECULE 1 (CLL-1) BINDING PROTEINS
|
JP2021512914A
(ja)
|
2018-02-08 |
2021-05-20 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
|
CN112368012A
(zh)
|
2018-02-08 |
2021-02-12 |
蜻蜓疗法股份有限公司 |
靶向nkg2d受体的抗体可变结构域
|
BR112020016944A2
(pt)
|
2018-02-20 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
|
AU2019225741A1
(en)
|
2018-02-20 |
2020-09-17 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
CA3135711A1
(en)
|
2018-04-03 |
2019-10-10 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
US20220025037A1
(en)
|
2018-04-03 |
2022-01-27 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
JP2021523140A
(ja)
|
2018-05-07 |
2021-09-02 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質
|
BR112020023299A2
(pt)
|
2018-05-16 |
2021-02-02 |
Dragonfly Therapeutics, Inc. |
proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos
|
EA202091977A1
(ru)
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
US20220153848A1
(en)
|
2018-08-08 |
2022-05-19 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
US20210317223A1
(en)
|
2018-08-08 |
2021-10-14 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
BR112021002278A2
(pt)
|
2018-08-08 |
2021-07-20 |
Dragonfly Therapeutics, Inc. |
proteínas que ligam nkg2d, cd16 e um antígeno associado a tumor
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
TW202033547A
(zh)
|
2018-10-23 |
2020-09-16 |
美商蜻蜓醫療公司 |
異二聚體fc融合蛋白
|
WO2020172189A1
(en)
|
2019-02-18 |
2020-08-27 |
Courier Therapeutics, Inc. |
BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
JP2022546454A
(ja)
|
2019-08-30 |
2022-11-04 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
がん処置のためのher2、nkg2dおよびcd16に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
|
JP2022551969A
(ja)
|
2019-10-15 |
2022-12-14 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Nkg2d、cd16およびflt3に結合するタンパク質
|
CA3175809A1
(en)
|
2020-04-22 |
2021-10-28 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
|
CN115836088A
(zh)
|
2020-05-06 |
2023-03-21 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和clec12a的蛋白质
|
BR112023002116A2
(pt)
|
2020-08-05 |
2023-04-25 |
Dragonfly Therapeutics Inc |
Proteínas que se ligam a nkg2d, cd16 e egfr
|
US20230034186A1
(en)
|
2021-03-03 |
2023-02-02 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
AR127162A1
(es)
|
2021-09-29 |
2023-12-27 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a nkg2d, cd16 y baff-r
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
WO2023154796A2
(en)
|
2022-02-09 |
2023-08-17 |
Dragonfly Therapeutics, Inc. |
Pharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
|
WO2023168384A2
(en)
|
2022-03-03 |
2023-09-07 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2
|